Kinapse Blog

Read our latest insights into the Life Sciences industry.

3 ways blockchain will change the pharmaceutical supply chain

Blockchain could revolutionise the pharma supply chain, solving big issues in logistics, counterfeiting, and patient usage. Follow the link to find out how.


Kinapse features in the International Track 200 for second year running

For the second consecutive year, Kinapse has ranked in the top 200 mid-market private companies with the fastest-growing overseas sales, according to the Sunday Times HSBC International Track 200.


Drug pricing affordability: how to clear the 5th Market Access hurdle

Fuelled by media scrutiny, drug affordability is becoming an increasingly powerful influence in market access decisions today. Learn how to overcome it.


Patient Centricity: how digital is giving patients control of managing their care

Lean Biotechs and patients themselves are using new technology to revolutionise the patient experience. In order to keep up, Pharma needs to significantly accelerate and strengthen its value proposition in the digital space.


Health Canada aligns with EMA on public clinical trial reporting – with a few key differences

Health Canada have drafted a guidance document relating to the planned public release of clinical trial documents, broadly in line with EMA Policy 0070. What are the key differences? How should your organisation prepare?


Why US organisations need to prepare for an equivalent to EMA policy 0070

A recently announced FDA pilot program suggests that the agency is taking steps towards implementing an equivalent to the EMA's policy 0070. US-based organisations should act now to prepare.


Kinapse signs the Armed Forces Covenant

On 20th March 2018, Kinapse was proud to sign the Armed Forces Covenant.  We were honoured to welcome Major General Chris Tickell CBE to our Wimbledon offices to celebrate with us and to countersign our Covenant on behalf of The Ministry of Defence.